Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tivozanib - AVEO Oncology/Kyowa Kirin

Next Previous
Drug Profile

Tivozanib - AVEO Oncology/Kyowa Kirin

Alternative Names: ASP-4130; AV-951; AV951 cpd; AVE-951; FOTIVDA; Fotivda; KHK-4951; Kil 8951; KRN-951; Tivopath; Tivozanib hydrochloride monohydrate; UNII-172030934T

Latest Information Update: 26 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kirin Brewery
  • Developer Astellas Pharma; AstraZeneca; AVEO Oncology; Bristol-Myers Squibb; EUSA Pharma; Institute Gustave-Roussy; Kyowa Kirin; Northwestern University; Pharmstandard
  • Class Antineoplastics; Eye disorder therapies; Isoxazoles; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase II Diabetic macular oedema; Liver cancer; Soft tissue sarcoma; Wet age-related macular degeneration
  • Suspended Colorectal cancer; Fallopian tube cancer; Gastrointestinal cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
  • No development reported Solid tumours

Most Recent Events

  • 30 May 2025 Efficacy data from a phase III trial in Renal cell carcinoma presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO 2025)
  • 13 Feb 2025 Efficacy, pharmacokinetics and adverse events data from phase III TiNivo-2 trial in Renal cell carcinoma presented at the Genitourinary Cancers Symposium (ASCO-GU-2025)
  • 16 Sep 2024 Efficacy data from the phase III TiNivo-2 trial in Renal cell carcinoma released by AVEO Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top